Precision Biosensor Inc.
Precision Biosensor, Inc. engages in the development, production, and sale of immune diagnostic kits in South Korea. It offers Exdia TRF Plus, an immunodiagnosis POCT platform; and Exdia PT10 and Exdia PT10S, a clinical chemistry POCT platform. The company was founded in 2009 and is headquartered in Daejeon, South Korea.
Precision Biosensor Inc. (335810) - Total Liabilities
Latest total liabilities as of September 2025: ₩28.93 Billion KRW
Based on the latest financial reports, Precision Biosensor Inc. (335810) has total liabilities worth ₩28.93 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Precision Biosensor Inc. - Total Liabilities Trend (2017–2024)
This chart illustrates how Precision Biosensor Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Precision Biosensor Inc. Competitors by Total Liabilities
The table below lists competitors of Precision Biosensor Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dynasty Gold Corp
PINK:DGDCF
|
USA | $542.41K |
|
Bartronics India Limited
NSE:ASMS
|
India | ₹50.40 Million |
|
Ascendant Resources Inc
OTCQB:ASDRF
|
USA | $32.84 Million |
|
Bluelinea SA
PA:ALBLU
|
France | €8.79 Million |
|
Electric Power Technology Limited
TWO:4529
|
Taiwan | NT$19.61 Million |
|
ALFOT Technologies Co., Ltd.
TWO:4553
|
Taiwan | NT$882.13 Million |
|
KD Chem Co. Ltd
KQ:221980
|
Korea | ₩30.42 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Precision Biosensor Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precision Biosensor Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precision Biosensor Inc. (2017–2024)
The table below shows the annual total liabilities of Precision Biosensor Inc. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩26.34 Billion | -13.49% |
| 2023-12-31 | ₩30.45 Billion | +18.79% |
| 2022-12-31 | ₩25.63 Billion | +47.62% |
| 2021-12-31 | ₩17.37 Billion | +243.30% |
| 2020-12-31 | ₩5.06 Billion | -49.07% |
| 2019-12-31 | ₩9.93 Billion | -28.86% |
| 2018-12-31 | ₩13.96 Billion | +8.42% |
| 2017-12-31 | ₩12.88 Billion | -- |